Literature DB >> 16127162

Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis.

Alessandro M Vannucchi1, Alessandro Pancrazzi, Paola Guglielmelli, Simonetta Di Lollo, Costanza Bogani, Gianna Baroni, Lucia Bianchi, Anna Rita Migliaccio, Alberto Bosi, Francesco Paoletti.   

Abstract

The abnormal megakaryocytopoiesis associated with idiopathic myelofibrosis (IM) plays a role in its pathogenesis. Because mice with defective expression of transcription factor GATA-1 (GATA-1(low) mutants) eventually develop myelofibrosis, we investigated the occurrence of GATA-1 abnormalities in IM patients. CD 34(+) cells were purified from 12 IM patients and 8 controls; erythroblasts and megakaryocytes were then obtained from unilineage cultures of CD 34(+) cells. Purified CD 61(+), GPA(+), and CD 34(+) cells from IM patients contained levels of GATA-1, GATA-2, and FOG-1 mRNA, as well as of GATA-2 protein, that were similar to controls. In contrast, CD 61(+) cells from IM patients contained significantly reduced GATA-1 protein. Furthermore, 45% of megakaryocytes in biopsies from IM patients did not stain with anti-GATA-1 antibody, as compared to controls (2%), essential thrombocythemia (4%), or polycythemia vera (11%) patients. Abnormalities in immunoreactivity for FOG-1 were not found, and no mutations in GATA-1 coding sequences were found. The presence of GATA-1(neg) megakaryocytes in bone marrow biopsies was independent of the Val 617 Phe JAK 2 mutation, making it unlikely that a downstream functional relationship exists. We conclude that megakaryocytes from IM patients have reduced GATA-1 content, possibly contributing to disease pathogenesis as in the GATA-1(low) mice and also representing a novel IM-associated marker.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127162      PMCID: PMC1698737          DOI: 10.1016/S0002-9440(10)62056-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis.

Authors:  Marie-Claire Martyré; Virginie Steunou; Marie-Caroline LeBousse-Kerdilès; Juana Wietzerbin
Journal:  Blood       Date:  2003-06-15       Impact factor: 22.113

2.  The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome.

Authors:  Hideo Harigae; Gang Xu; Tomohiro Sugawara; Izumi Ishikawa; Tsutomu Toki; Etsuro Ito
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

Review 3.  Transplant decision-making strategies in the myeloproliferative disorders.

Authors:  Steven M Fruchtman
Journal:  Semin Hematol       Date:  2003-01       Impact factor: 3.851

4.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Authors:  Liat Rainis; Dan Bercovich; Sabine Strehl; Andrea Teigler-Schlegel; Batia Stark; Jan Trka; Ninette Amariglio; Andrea Biondi; Inna Muler; Gideon Rechavi; Helena Kempski; Oskar A Haas; Shai Izraeli
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

Review 5.  Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.

Authors:  Sandeep Gurbuxani; Paresh Vyas; John D Crispino
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

Review 6.  Inherited thrombocytopenia: when a low platelet count does not mean ITP.

Authors:  Jonathan G Drachman
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

Review 7.  The forgotten myeloproliferative disorder: myeloid metaplasia.

Authors:  Ayalew Tefferi
Journal:  Oncologist       Date:  2003

8.  Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.

Authors:  Hédia Chagraoui; Emiko Komura; Micheline Tulliez; Stéphane Giraudier; William Vainchenker; Françoise Wendling
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

9.  Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice.

Authors:  Lucia Centurione; Angela Di Baldassarre; Maria Zingariello; Domenico Bosco; Valentina Gatta; Rosa Alba Rana; Vincenzo Langella; Antonio Di Virgilio; Alessandro M Vannucchi; Anna Rita Migliaccio
Journal:  Blood       Date:  2004-08-03       Impact factor: 22.113

10.  GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant.

Authors:  Anna Rita Migliaccio; Rosa Alba Rana; Massimo Sanchez; Rodolfo Lorenzini; Lucia Centurione; Lucia Bianchi; Alessandro Maria Vannucchi; Giovanni Migliaccio; Stuart H Orkin
Journal:  J Exp Med       Date:  2003-02-03       Impact factor: 14.307

View more
  34 in total

1.  CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.

Authors:  Maria Verrucci; Alessandro Pancrazzi; Miguel Aracil; Fabrizio Martelli; Paola Guglielmelli; Maria Zingariello; Barbara Ghinassi; Emanuela D'Amore; José Jimeno; Alessandro M Vannucchi; Anna Rita Migliaccio
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

Review 2.  Preclinical models for drug selection in myeloproliferative neoplasms.

Authors:  Niccolò Bartalucci; Costanza Bogani; Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 3.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

4.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

5.  Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Authors:  Christophe Desterke; Christophe Martinaud; Bernadette Guerton; Lisa Pieri; Costanza Bogani; Denis Clay; Frederic Torossian; Jean-Jacques Lataillade; Hans C Hasselbach; Heinz Gisslinger; Jean-Loup Demory; Brigitte Dupriez; Claude Boucheix; Eric Rubinstein; Sophie Amsellem; Alessandro M Vannucchi; Marie-Caroline Le Bousse-Kerdilès
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

6.  Lysyl oxidase is associated with increased thrombosis and platelet reactivity.

Authors:  Shinobu Matsuura; Rongjuan Mi; Milka Koupenova; Alexia Eliades; Shenia Patterson; Paul Toselli; Jonathan Thon; Joseph E Italiano; Philip C Trackman; Nikolaos Papadantonakis; Katya Ravid
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

7.  Busy signal: platelet-derived growth factor activation in myelofibrosis.

Authors:  Anna E Marneth; Ann Mullally
Journal:  Haematologica       Date:  2020-08       Impact factor: 9.941

8.  Differential localization of P-selectin and von Willebrand factor during megakaryocyte maturation.

Authors:  M Zingariello; M E Fabucci; D Bosco; A R Migliaccio; F Martelli; R A Rana; E Zetterberg
Journal:  Biotech Histochem       Date:  2010-04-28       Impact factor: 1.718

9.  A novel interaction between megakaryocytes and activated fibrocytes increases TGF-β bioavailability in the Gata1(low) mouse model of myelofibrosis.

Authors:  Maria Zingariello; Alessandra Ruggeri; Fabrizio Martelli; Manuela Marra; Laura Sancillo; Ilaria Ceglia; Rosa Alba Rana; Anna Rita Migliaccio
Journal:  Am J Blood Res       Date:  2015-12-25

Review 10.  Novel targets to cure primary myelofibrosis from studies on Gata1low mice.

Authors:  Maria Zingariello; Fabrizio Martelli; Paola Verachi; Claudio Bardelli; Francesca Gobbo; Maria Mazzarini; Anna Rita Migliaccio
Journal:  IUBMB Life       Date:  2019-11-21       Impact factor: 3.885

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.